Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress

  • Arch Physiol Biochem. 2022 Dec;128(6):1681-1686. doi: 10.1080/13813455.2020.1788605.
Leila Safaeian  1 ,  Mina Mirian  2 ,  Shahryar Bahrizadeh  1
Affiliations
  • 1. Department of Pharmacology and Toxicology, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
  • 2. Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
PMID: 32619370 DOI: 10.1080/13813455.2020.1788605
Abstract

Context: Recent surveys have shown an association between proprotein convertase subtilisin/kexin type 9 (PCSK9) and oxidative stress.

Objective: In this investigation, the effect of evolocumab an anti-PCSK9 antibody was assessed against oxidative damage caused by hydrogen peroxide (H2O2) in human umbilical vein endothelial cells (HUVEC).

Material and methods: Viability of HUVEC was measured by MTT assay. Hydroperoxides and malondialdehyde (MDA) levels, and ferric reducing antioxidant power (FRAP) were detected in HUVEC that pre-treated with evolocumab and, then exposed to H2O2.

Results: Evolocumab significantly prevented the cytotoxicity induced by H2O2 at the concentrations of 5-100 µg/ml. Pre-treatment of HUVEC with evolocumab reduced hydroperoxides and MDA levels and also increased FRAP value in intra- and extra-cellular mediums compared with H2O2 stimulated cells at different concentration ranges.

Conclusion: This study displayed anti-oxidative and cytoprotective activities of evolocumab against oxidative damage caused by H2O2 in endothelial cells.

Keywords
Antioxidants; HUVEC; cell viability; evolocumab; oxidative stress.
Products